Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Charalampaki, Cleopatra, M.D.
In patients requiring neurosurgical oncological Intervention using endoscopic devices, a mini laser probe will be administered through the endoscopic device to characterize in vivo the tissue by thousandfold magnification down to the cellular level (so-called optical biopsy). Magnification is presented to the neurosurgeon in time to better differentiate between healthy and pathological tissue. Post-surgery results of in-vivo Differentiation will then be compared to histocytopathological findings.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients administered to the department of neurosurgery requiring neurosurgery due to either diagnosed gliomata (40 patients) or diagnosed subcranial tumors adjacent to or already invading neuronal structures (20 patients)
patients having given informed consent
You may not be if
severe concomitant diseases probably negatively influencing the participation in this clinical trial
cardial infarction or stroke within the preceding 12 months
Treatment resistant hypertonus (systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg or a combination of both
Pulmonic diseases that might result in an advanced risk for anesthetic measurements
Patients being vaccinated with live vaccines (14 days Prior) or contra Influenza (7 days Prior) to start of the study
All concomitant findings that might increase in the eyes of the investigator the risk of participation
